Rodman & Renshaw
Rodman & Renshaw is a New York boutique investment bank focused on the lower middle market, operating under a brokerage name that dates to 1951. It arranges public offerings, registered direct offerings and at-the-market financings for growth companies, and its research covers small-cap biotechnology.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 712M
- Actions
- 712M
- Ratings / Price targets
- 7 / 0
- Initiations
- 6
- Buy-rated
- 100%of 7 rated
- On record
- Mar 2012 – Aug 2026
Overview
At our core is an entrepreneurial spirit, an interest in developing new ideas, and a penchant for acting on promising opportunities.
The research team, led since January 2026 by director of research Michael King, consists of biotechnology analysts, and its 2026 coverage list is made up of small-cap drug developers. Its research is written for institutional investors, from large asset managers to sector specialists, and its bankers present themselves as long-term partners to growth companies. Buy ratings made up about 88% of the rated universe in January 2025.
Rodman & Renshaw was founded in 1951 and was a Chicago brokerage when Mexico's Abaco Casa de Bolsa took control in 1994; it filed for Chapter 7 liquidation in 1998. A New York-based Rodman & Renshaw listed on Nasdaq in 2007 through a reverse merger, renamed its parent Direct Markets Holdings in June 2012 and stopped broker-dealer operations that September. H.C. Wainwright used the name for a research unit from 2015; Rodman & Renshaw LLC now operates as a separate, affiliated broker-dealer.
Milestones
- 1951
Rodman & Renshaw founded
- 1994
Mexico's Abaco Casa de Bolsa acquires control
- 1998
Chicago brokerage files for Chapter 7 liquidation
- 2007
Lists on Nasdaq via reverse merger with Enthrust
- 2012
Parent renamed Direct Markets Holdings; broker-dealer ceases operations
- 2015
Name revived for an H.C. Wainwright research unit
Firm facts
- Legal name
- Rodman & Renshaw LLC
- Type
- Boutique
- Founded
- 1951
- Headquarters
- New York, United States
- Chief Executive Officer
- David Dinkin
- Director of Research
- Michael King
- Rating scale
- BuyNeutralSell
- Website
- rodm.com
Research philosophy
Rodman & Renshaw says its analysts seek overlooked and undervalued companies. Its team includes researchers with doctorates and industry veterans, who assess how a company's business model and industry conditions affect its investment value.
Rating methodology
Ratings are Market Outperform (Buy), Market Perform (Neutral) and Market Underperform (Sell), set relative to a passive index of same-sector stocks.
Coverage12M
Sectors
Most covered24M
Recent actions
| Date | Stock | Rating action | Rating |
|---|---|---|---|
| Aug 31 |  Quantum BioPharma Ltd.QNTM | Initiate | Buy |
| Jul 30 |  Actuate Therapeutics IncACTU | Initiate | Buy |
| Jul 23 |  Zentalis Pharmaceuticals, Inc.ZNTL | Initiate | Buy |
| Jul 21 |  Eledon Pharmaceuticals, Inc.ELDN | Initiate | Buy |
| Jul 7 |  Atossa Therapeutics, Inc.ATOS | Initiate | Buy |
| Jun 30 |  vTv Therapeutics Inc.VTVT | Initiate | Buy |
| May 11 |  SAB Biotherapeutics, Inc.SABS | Reiterate | Buy |
| Sep 26, 2024 |  Biomea Fusion, Inc.BMEA | Upgrade | Neutral →Buy |
| Sep 13, 2024 | EBEmergent BioSolutions Inc.EBS | Reiterate | Buy |
| Jul 2, 2024 | CGCognition Therapeutics, Inc.CGTX | Reiterate | Buy |
| Jul 2, 2024 | ANAnnovis Bio, Inc.ANVS | Reiterate | Buy |
| Nov 25, 2020 | EFEnergy Focus, Inc.EFOI | Reiterate | Buy |